Conjunctivitis (also known as pink eye) is a common condition, affecting approximately 6 million Americans each year.\(^1\) Conjunctivitis can be caused by virus, bacteria, or allergens, and prevalence varies based on time of year and geographic location.\(^2\) Globally, up to 70% of acute conjunctivitis is viral,\(^3\) and up to 90% of viral conjunctivitis is caused by Adenovirus.\(^4\) In the United States, approximately one in four patients with acute conjunctivitis have confirmed Adenoviral conjunctivitis. Adenovirus can live on inanimate surfaces for 4-5 weeks\(^4\) and is highly contagious. Transmission rates of up to 50% have been reported;\(^4\) modes of transmission are hand-to-eye and airborne respiratory droplets. Co-infections occur in 1-2% of conjunctivitis cases and do not require antibiotic therapy,\(^5,6\) and misdiagnosis of conjunctivitis occurs in approximately 50% of all conjunctivitis cases.\(^2\)

### ACUTE CONJUNCTIVITIS

**AdenoPlus®** is the first and only FDA cleared, CLIA-waived, point-of-care (POC) test that detects all serotypes known to typically cause Adenoviral conjunctivitis.

- Results in 10 minutes
- Single-use disposable test
- Utilizes direct tear sample; no extraction or dilution steps
- No ancillary analyzer, equipment, or reagent required
- Dedicated CPT reimbursement code (87809QW)
- Accurate – 90% sensitive and 96% specific\(^7\)

### Overlap in Clinical Signs and Symptoms of Acute Conjunctivitis

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Viral</th>
<th>Bacterial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Redness/infected conjunctiva</td>
<td>81%</td>
<td>83%</td>
</tr>
<tr>
<td>Purulent discharge</td>
<td>25%</td>
<td>28%</td>
</tr>
<tr>
<td>Mucoidal discharge</td>
<td>19%</td>
<td>17%</td>
</tr>
<tr>
<td>Irritation/foreign body sensation</td>
<td>19%</td>
<td>17%</td>
</tr>
<tr>
<td>Watery discharge/tearing</td>
<td>50%</td>
<td>39%</td>
</tr>
<tr>
<td>Follicles</td>
<td>47%</td>
<td>42%</td>
</tr>
<tr>
<td>Itching</td>
<td>38%</td>
<td>33%</td>
</tr>
</tbody>
</table>

AdenoPlus® Results in 10 minutes, Single-use disposable test, Utilizes direct tear sample; no extraction or dilution steps, No ancillary analyzer, equipment, or reagent required, Dedicated CPT reimbursement code (87809QW), Accurate – 90% sensitive and 96% specific.
NATIONAL CAMPAIGN – CHOOSING WISELY®

The American Academy of Ophthalmology recently partnered with the American Board of Internal Medicine’s national campaign, Choosing Wisely, to publicize the importance against providing antibiotics to patients with Adenoviral conjunctivitis.

Originally conceived by the National Physicians Alliance, the Choosing Wisely program helps physicians and patients engage about proper testing and treatment to aid in reducing unnecessary tests and antibiotics and to focus on appropriate and necessary treatments.

CLINICAL AND ECONOMIC VALUE

Conjunctivitis, due to its common occurrence, contagiousness, and potentially debilitating morbidities, is a global economic burden. By helping improve accuracy and timeliness of diagnosis, AdenoPlus may help facilitate appropriate management and treatment of conjunctivitis, resulting in overall reduction in spread of disease and reduction in total healthcare costs.

- Antibiotic resistance costs in the United States may create up to $20 billion a year in excess direct healthcare costs; lost productivity may add an additional $15 billion in annual costs
- Approximately $800 million is spent annually in the United States to treat conjunctivitis
- Employee absenteism, lost wages, and decreased productivity attributable to conjunctivitis represent $1.9 billion of additional indirect costs in the United States each year
- Adenoviral conjunctivitis is associated with significant morbidity, such as decreased visual acuity or light sensitivity from subepithelial infiltrates, chronic epiphora from lacrimal drainage problems, or visual loss from conjunctival foreshortening and symblepharon formation.

RAPID PATHOGEN SCREENING, INC. (RPS)

RPS’s novel POC tests bridge the gap between current clinical practice and the standard of care, helping physicians provide the best possible patient management while acting as good stewards of therapeutic resources. Founded in 2004, RPS is an emerging developer, manufacturer, and marketer of POC diagnostic tests based in Sarasota, Florida. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment.

References: